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Abstract
Background: Prostatitis and sexually transmitted diseases (STDs) have been positively associated with prostate cancer in
previous case-control studies. However, results from recent prospective studies have been inconclusive.
Methodogy/Principal Findings: We investigated the association between prostatitis, STDs, and prostate cancer among
African American, Asian American, Latino, and White participants of the California Men’s Health Study. Our analysis included
68,675 men, who completed a detailed baseline questionnaire in 2002–2003. We identified 1,658 incident prostate cancer
cases during the follow-up period to June 30, 2006. Cox proportional hazards models were used to estimate relative risks
and 95% confidence intervals. Overall, men having a history of prostatitis had an increased risk of prostate cancer than men
with no history (RR=1.30; 95% CI: 1.10–1.54). Longer duration of prostatitis symptoms was also associated with an increased
risk of prostate cancer (P trend=0.003). In addition, among men screened for prostate cancer (1 or 2 PSA tests), a non-
significant positive association was observed between prostatitis and prostate cancer (RR=1.10; 95% CI: 0.75–1.63). STDs
were not associated with overall prostate cancer risk. In racial/ethnic stratified analysis, Latinos reporting any STDs had an
increased risk of disease than those with no STDs (RR=1.43; 95% CI: 1.07–1.91). Interestingly, foreign-born Latinos displayed
a larger risk associated with STDs (RR=1.87; 95% CI: 1.16–3.02) than U.S. born Latinos (RR=1.15; 95% CI: 0.76–3.02).
Conclusion: In summary, results from this prospective study suggest that prostatitis and STDs may be involved in prostate
cancer susceptibility. While we cannot rule out the possible influence of incidental detection, future studies are warranted to
further investigate the role of infectious agents related to prostatitis and STDs in prostate cancer development.
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Introduction
Prostate cancer is the most commonly diagnosed cancer among
men in the United States [1]. The etiological factors driving the
development of prostate cancer have yet to be fully identified and
emerging evidence has suggested that infectious agents may be
important risk factors for disease. Prostatitis, a commonly
occurring condition that includes acute or chronic bacterial
infection within the prostate [2,3,4,5], and sexually transmitted
diseases (STDs) [6,7,8,9,10,11,12] such as syphilis and gonorrhea
have been linked to an increased risk of prostate cancer. It is
theorized that chronic inflammation within the prostate due to the
exposure of microbial agents stimulates the production of
inflammatory cytokines and reactive oxygen species, leading to
increased cellular proliferation and possibly carcinogenesis
[13,14].
Prior epidemiological studies have examined the role of
prostatitis, STDs, and prostate cancer using primarily a case-
control approach with serological studies of STDs and prostate
cancer using a nested case-control design. A large meta-analysis of
29 case-control studies reported men having any history of STDs
had a significant 1.5-fold increased risk of prostate cancer [6].
These collective findings suggest that STDs may be involved in
prostate cancer. However, the potential for recall bias in case-
control studies of gonorrhea and syphilis highlights the need for
cohort studies, drawing on their prospective design to eliminate
this potential bias. To date, there have been three prospective
studies of self-reported prostatitis and/or STDs and prostate
cancer [3,12,15]. The Prostate, Lung, Colorectal, and Ovarian
(PLCO) Cancer Screening trial reported no association for syphilis
and gonorrhea yet a borderline positive association was observed
with any STDs including those identified by serological evidence
[12]. The Health Professional Follow-up Study reported no overall
association between prostatitis, gonorrhea, syphilis, and prostate
cancer [3]. In a small nested case-control study within another
Kaiser Permanente cohort study, no association was observed
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positive association was seen between gonorrhea and prostate
cancer [15].
To further investigate the relationship between prostatitis,
STDs, and prostate cancer risk, we conducted a large prospective
cohort study of African American, Asian American, Latino, and
White men participating in the California Men’s Health Study.
The sociodemographic diversity of this study population and its
wide range in histories of prostatitis and STDs makes this cohort
an excellent resource to examine the influence of these conditions
on the development of prostate cancer.
Methods
Study Population
The California Men’s Health Study (CMHS) is a large cohort
study of 84,170 men from Northern and Southern California
Kaiser Permanente. A description of the methods used to create
the cohort and the characteristics of the cohort members have
been published elsewhere [16]. In brief, participants between the
ages of 45 and 69 years were recruited from 2002–2003 and
completed a self-administered questionnaire that included infor-
mation regarding demographic characteristics, health status,
residential history in the United States, and lifestyle behaviors.
The cohort is comprised of predominantly four racial/ethnic
groups: African Americans, Asian Americans, Latinos, and
Whites. This study was approved by the Institutional Review
Boards of Kaiser Permanente Northern and Southern California
and all study participants signed an informed consent before
participating.
For the present study, we excluded men: diagnosed with any
cancer prior to completion of questionnaire with the exception of
localized, non-melanoma skin cancer (n=5,608); self-reported
prostate cancer (n=8,739); had a prostatectomy prior to
questionnaire (n=16); missing prostate cancer diagnosis date
(n=1); missing race/ethnicity (n=664); missing death date
(n=12); no active membership on the date of questionnaire
(n=995). The remaining 68,675 men were included for analysis.
Surveillance
Cohort subjects were followed from the date of completed
questionnaire until the earliest occurrence of any of the following
events: prostate cancer diagnosis, radical prostatectomy, .90 day
gap in Kaiser Permanente membership, death, or end of study
period (June 30, 2006). Prostate cancer diagnoses were identified
through Northern and Southern California Kaiser Permanente
Cancer Registries, which provide data to the Surveillance,
Epidemiology, and End Results (SEER) program and are
considered .99% complete. Stage of disease and tumor grade
were defined according to the SEER classification system. Non-
aggressive and aggressive disease were defined based on stage and
grade information. Localized tumors confined within the prostate
that were well or moderately differentiated (SEER grade I or II)
were classified as non-aggressive disease. Regional or metastatic
tumors or localized tumors that were poorly differentiated or
undifferentiated (SEER grade III or IV) were categorized as
aggressive disease.
Assessment of Prostatitis and Sexually Transmitted
Diseases from Baseline Questionnaire
The baseline questionnaire asked subjects to report: a) have you
ever had prostatitis or prostatic infection: yes, no; b) how long did
the symptoms persist: ,1 year, 1–2 years, 3–5 years, 6–10 years,
.10 years. In addition, information on five STDs and bladder
infection were assessed in response to the question ‘‘how often
have you ever had any of the following diseases’’: gonorrhea or
‘the clap’; syphilis; Chlamydia; genital warts (HPV); genital herpes;
bladder infection. We categorized history of prostatitis as no, yes,
missing and duration of prostatitis symptoms as none, ,1 year,
.1 year, missing. STD history was categorized for any STDs and
each specific STD (no, yes, missing) and number of STDs (0, 1, .2
(multiple different STDs or repeated episodes of the same STD),
missing). We included missing terms for prostatitis and STDs in all
analysis; these terms demonstrated no association with risk.
Statistical Analysis
Hazard ratios for prostate cancer incidence, referred to in this
report as relative risks (RR) and 95% confidence intervals (CI)
were estimated using Cox proportional hazards regression with
age as the time scale. Subjects were considered to have entered the
study at date of questionnaire and were followed until the earliest
occurrence of any of these events: prostate cancer diagnosis,
radical prostatectomy, a .90 day gap in Kaiser Permanente
membership, death, or the end of the study period (June 30, 2006).
All Cox models were adjusted for the following covariates that
were associated with our model of prostate cancer risk: age, racial/
ethnic group, family history of prostate cancer (no, yes), body mass
index (BMI; ,25 kg/m
2, 25–30 kg/m
2, .30 kg/m
2), and income
(,$20,000, $20,000–$39,999, $40,000–$59,999, $60,000–$79,999,
$80,000–$99,999, .$100,000). Other potential confounders were
considered such as education, smoking, ejaculation history from
ages 20–29/30–39/40–49/past year, sexual orientation, diabetes,
sildenafil (Viagra) use, and testosterone use. Because adjustment
for these potential confounders did not notably alter risk estimates,
they were not included in our final multivariable models. Tests of
heterogeneity for prostatitis/STDs were conducted for severity of
disease and race/ethnicity, respectively. Stratified analysis by
severity of disease and race/ethnicity are presented to evaluate the
consistency of effects across groups.
Stratified analyses were also conducted to evaluate effects
among certain subgroups. To investigate possible detection bias
due to prostate cancer screening by PSA testing, we compared
associations between prostatitis, STDs, and prostate cancer among
men having no PSA tests, 1 or 2 PSA tests, and 3 or more PSA
tests, from the date of questionnaire to the end of follow-up based
on laboratory records of PSA testing. In addition, we evaluated the
effects of prostatitis and prostate cancer stratified by history BPH,
a condition related to prostatitis and the incidental detection of
prostate cancer. To further examine prostate cancer associations
among Latinos and Asian Americans, major immigrant groups to
the U.S., we compared effects between U.S. born and foreign-
born men.
All statistical significance levels (P values) presented are two-
sided. Analyses were performed using SAS 9.1 (SAS Institute, Inc.,
Cary, North Carolina).
Results
Baseline characteristics of men in the study population by
history of prostatitis and STDs are presented in Table 1. Men
having a history of prostatitis were more likely to be White and
tended to have a family history of prostate cancer, a graduate
degree, higher income (.$100,000), 3 or more PSA tests, and
benign prostatic hyperplasia (BPH) than those without prostatitis.
Men reporting a history of any STD were more commonly African
American or Latino, had a family history of prostate cancer, were
current/former smokers than those without a STD history. For
men with gonorrhea and syphilis, a profile generally similar to that
Prostatitis, STDs, CaP
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with gonorrhea or syphilis were more likely to have only
completed a high school education.
Of 68,675 men in this study, 6.2% reported a history of
prostatitis with 4.7% having prostatitis symptoms for less than one
year (Table 2). Whites (7.2%) were more likely to report having a
history of prostatitis than other racial/ethnic groups. Latinos
displayed the longest duration (.1 year) of prostatitis symptoms.
Overall, 26.3% of men in this study reported a history of any STD
with 14.7% of men having two or more previous STDs (Table 2).
The most commonly reported STD was gonorrhea (17.1%)
followed by genital herpes (6.2%), genital warts (5.7%), Chlamydia
(3.6%), and syphilis (2.2%). African Americans were more likely to
report a history of any STD (59.9%) than Latinos (28.8%), Whites
(23.7%), and Asian Americans (12.5%). Similarly, African
Americans were more likely to report having multiple STDs
(39.5%) with a proportion that was more than two-fold higher
than that reported for any other racial/ethnic group. Gonorrhea
was the most often reported STD among African Americans
(52.4%) and Latinos (19.5%) while bladder infection was the most
frequently reported genitourinary infection among Whites (20.5%)
and Asian Americans (9.8%).
Of 68,675 cohort participants, 1,658 men were diagnosed with
prostate cancer during the follow-up period from questionnaire
completion to June 30, 2006. The maximum follow-up time was 4
years with a median of 2 years. Non-aggressive disease accounted
for 64.8% of the cases with the remaining 35.2% of these cases
having aggressive disease. Of the 1658 cases, 222 were categorized
as regional/distant (SEER stages II–IV) and 450 were categorized
as poorly differentiated/undifferentiated (SEER grade III/IV).
The adjusted relative risks of prostate cancer by prostatitis and
STD histories are shown in Table 3. Men reporting a history of
prostatitis had a significant 1.3-fold increased risk of prostate
cancer in comparison to those with no history of prostatitis (95%
Table 1. Baseline charactersitics of men according to prostatitis and STD history, California Men’s Health Study, 2002–2006.
Prostatitis* STDs* Gonorrhea* Syphilis*
No
(n=63,613)
Yes
(n=4,228)
No
(n=40,720)
Yes
(n=26,010)
No
(n=55,347)
Yes
(n=11,378)
No
(n=63,499)
Yes
(n=1,437)
Age mean (SD) 57.2 (6.9) 58.4 (6.7) 57.3 (7.0) 57.3 (6.7) 57.3 (7.0) 57.5 (6.6) 57.3 (6.9) 56.5 (6.7)
Race/ethnicity % African American 8.4 7.5 4.5 14.5 4.8 25.8 7.6 21.8
Asian American 9.0 4.6 11.2 4.5 9.7 3.9 8.9 6.2
Latino 16.4 14.2 15.9 16.4 15.5 18.3 15.4 22.8
White 61.3 71.4 62.9 61.3 65.1 48.6 63.5 45.0
Other 4.9 2.3 5.5 3.3 4.9 3.4 4.7 4.3
Family history of prostate
cancer* %
Yes 11.9 14.8 11.5 13.0 12.0 12.5 31.0 31.7
BMI % ,25 kg/m
2 27.4 29.5 28.1 26.5 27.7 26.1 27.3 31.6
25–30 kg/m
2 46.0 47.8 46.0 46.4 46.0 47.0 46.3 42.4
.30 kg/m
2 26.6 22.7 25.9 27.1 26.3 26.9 26.4 26.0
Smoking % never 43.6 44.3 46.8 38.5 46.2 31.5 44.2 35.9
current 11.1 9.0 9.9 12.6 9.9 15.8 10.6 18.4
former 45.3 46.7 43.3 49.0 43.9 52.7 45.3 45.8
Education % ,=High school 19.0 13.4 18.8 17.7 17.7 21.3 17.5 22.5
Some college 21.1 20.6 21.7 20.2 21.7 18.5 21.7 18.3
Bachelor’s degree 35.0 31.0 33.6 36.9 33.7 40.0 33.8 35.6
Graduate degree 25.0 35.0 26.0 25.1 26.9 20.2 27.0 23.5
Income % ,$20,000 4.8 4.3 4.4 4.8 4.2 6.1 4.3 9.0
$20,000–$39,999 15.5 14.1 14.8 16.0 14.5 18.6 14.7 23.2
$40,000–$59,999 19.4 17.9 19.3 19.5 19.0 21.1 19.2 22.8
$60,000–$79,999 18.9 17.0 19.1 18.5 18.9 18.6 19.0 15.2
$80,000–$99,999 14.0 14.2 14.2 13.9 14.3 13.2 14.3 11.8
.$100,000 27.5 32.5 28.3 27.4 29.1 22.3 28.6 18.1
Kaiser California Region % Northern 53.7 52.3 54.3 52.6 54.3 50.7 54.0 47.1
Southern 46.3 47.7 45.7 47.4 45.7 49.3 46.0 52.9
Previous history of PSA
testing
{ %
None 57.3 55.8 56.8 58.3 56.7 59.4 56.9 62.5
1 or 2 test 27.0 23.2 27.0 26.2 27.2 24.7 27.0 21.7
3 or more tests 15.7 21.0 16.3 15.6 16.1 16.0 16.1 15.8
History of BPH % Yes 16.4 52.8 16.0 23.3 18.6 19.8 18.7 18.3
*Numbers do not add to 68,675 subjects due to missing responses.
{History of at least number of PSA tests from baseline to follow-up period.
doi:10.1371/journal.pone.0008736.t001
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prostatitis symptoms had a further increased risk of prostate cancer
(P trend=0.003). A significant difference was seen between the
association of prostatitis and severity of disease (P heterogene-
ity=0.03; Table 3). History of prostatitis was significantly
associated with an increased risk of non-aggressive disease, yet
no association was observed between prostatitis and aggressive
disease. In addition, the association between prostatitis and non-
aggressive prostate cancer remained significant with adjustment of
number of PSA tests (RR=1.52; 95% CI: 1.25–1.86). There was
no overall association between history of any STDs and prostate
cancer. Of the five specific STDs examined, a history of genital
warts was inversely associated with prostate cancer risk
(RR=0.77; 95% CI: 0.60–0.99).
In racial/ethnic-specific analysis, Latinos and Whites had a
significantly increased risk of prostate cancer associated with both
prostatitis history and duration (Table 4). Latinos and Whites had
a 1.8 to 2-fold significantly increased risk of prostate cancer among
those having prostatitis symptoms for .1 year in comparison to
those with no symptoms (Latino P trend=0.044; Whites P
trend=0.002). Latinos also had a significantly increased risk of
prostate cancer associated with history of any STDs (RR=1.43;
95% CI: 1.07–1.91) and gonorrhea (RR=1.39; 95% CI: 1.01–
1.91). Asian Americans experienced a significant positive associ-
ation with history of syphilis and Chlamydia, while the Other
racial/ethnic group had a significantly increased risk associated
with bladder infections. Notably, among African Americans,
where 5.5% reported a history of prostatitis and 59.9% reported a
history of STDs, there were no associations for either prostatitis or
STDs and risk of prostate cancer.
Since many Latinos and Asian Americans are immigrants to the
U.S., we explored whether their risks associations differed by place
of birth (Table 5). For Latinos, we observed larger relative risks for
history of prostatitis and STDs among those foreign-born. In
particular, a significant 1.9-fold increased risk of prostate cancer
was associated with history of STDs among Latinos born in either
Mexico or Central/South America (P=0.014) while no associa-
tion was seen among Latinos born in the United States.
Gonorrhea, a more symptomatic STD, was significantly associated
with prostate cancer risk among foreign-born Latinos (RR=1.95;
95% CI: 1.20–3.16) but not among U.S. born Latinos. For Asian
Americans, we observed a similar pattern as seen with Latinos
such that larger effects were detected among those foreign-born in
comparison to those born in the United States. A significant
association between prostatitis and prostate cancer was seen for
foreign-born Asian Americans (RR=2.66; 95% CI: 1.02–6.95).
In a stratified analysis of PSA screening to examine the potential
influence of detection bias, prostatitis displayed positive associa-
tions with prostate cancer risk across all strata of number of
previous laboratory PSA tests during follow-up with significant
associations seen for men having no prior PSA testing and those
having 3 or more PSA tests, RR=1.34; 95% CI: 1.05–1.70 and
RR=1.42; 95% CI: 1.03–1.94, respectively (P heterogene-
ity=0.215; Table 6). Adjusting both for the time-fixed number
Table 2. Distribution of prostatitis and STDs among all men and by racial/ethnic group, California Men’s Health Study, 2002–2006.
All (N=68,675)
African Americans
(n=5,784)
Asian Americans
(n=6,024)
Latinos
(n=11,213)
Whites
(n=42,409)
Others
(n=3,245)
Prostatitis %* No 93.8 94.5 96.7 94.6 92.8 96.9
Yes 6.2 5.5 3.3 5.5 7.2 3.1
Duration of prostatitis %* None 94.0 94.9 96.9 94.8 93.0 97.0
,1 year 4.7 3.9 2.2 3.6 5.6 2.1
$1 year 1.3 1.3 0.9 1.6 1.4 0.9
STDs%* No 73.7 40.1 87.5 71.2 76.3 82.5
Yes 26.3 59.9 12.5 28.8 23.7 17.5
Number of STDs %* 0 73.9 41.2 85.7 71.7 76.5 81.6
1 11.4 19.3 6.0 12.4 11.1 8.1
$2 14.7 39.5 8.3 15.9 12.4 10.2
STDs and bladder infection* No 61.0 32.9 79.5 60.2 61.7 72.1
Yes 39.0 67.1 20.5 39.8 38.4 27.9
Gonorrhea %* No 83.0 47.6 92.4 80.5 86.7 87.6
Yes 17.1 52.4 7.6 19.5 13.3 12.4
Syphilis %* No 97.8 93.9 98.5 96.8 98.4 98.0
Yes 2.2 6.1 1.6 3.3 1.6 2.0
Chlamydia %* No 96.4 90.7 98.9 97.3 96.4 98.4
Yes 3.6 9.3 1.1 2.7 3.6 1.6
Genital warts %* No 94.3 93.1 97.7 94.3 93.7 97.2
Yes 5.7 6.9 2.3 5.7 6.3 2.8
Genital herpes %* No 93.8 91.3 96.9 93.9 93.5 97.5
Yes 6.2 8.7 3.1 6.1 6.5 2.5
Bladder infection %* No 81.1 78.6 90.2 82.4 79.5 86.0
Yes 18.9 21.4 9.8 17.6 20.5 14.0
*numbers do not add to 68,675 due to missing responses.
doi:10.1371/journal.pone.0008736.t002
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number of PSA tests during follow-up, prostatitis remained
significantly associated with prostate cancer risk (RR=1.30;
95% CI: 1.10–1.55 and RR=1.25; 95% CI: 1.03–1.52,
respectively). In addition, we found no evidence of heterogeneity
by age (,55 years and .55 years) among men having 1 or 2 PSA
tests, more likely representing those who are routinely screened (P
heterogeneity=0.607). Prostatitis was not associated with prostate
cancer among men with no history of BPH (RR=1.07; 95% CI:
0.78–1.47) as well as among men with a history of BPH
(RR=1.16; 95% CI: 0.93–1.44). For STDs, we observed no
difference by PSA testing (data not shown). Among foreign-born
Latinos, STD history was significantly associated with prostate
cancer among those with no prior PSA screening (RR=2.16; 95%
CI: 1.20–3.87) and non-significant positive associations were
observed among men having 1 or 2 PSA tests and 3 or more tests,
RR=1.33; 95% CI: 0.46–3.86 and RR=3.51; 95% CI: 0.58–
21.02, respectively, with a P heterogeneity=0.491.
Discussion
In the current study, we investigated whether prostatitis and
STDs influenced the risk of prostate cancer among men enrolled
in the California Men’s Health Study. In this multiethnic study of
over 68,000 men, overall a history of prostatitis and longer
duration of prostatitis symptoms was associated with an increased
risk of prostate cancer. Overall, STD history was not associated
with prostate cancer. In racial/ethnic stratified analysis, STD
history was associated with prostate cancer risk among Latinos
with those foreign-born experiencing a greater risk of prostate
cancer than those born in the United States.
Prostatitis includes several conditions that are categorized by the
National Institutes of Health as: (I) acute bacterial prostatitis; (II)
chronic bacterial prostatitis; (III) chronic prostatitis/chronic pelvic
pain syndrome (a) inflammatory and (b) non-inflammatory; (IV)
asymptomatic inflammatory prostatitis [17]. These conditions
present with various genitourinary symptoms, causing men to seek
Table 3. Multivariate relative risks and 95% CIs of prostate cancer associated with prostatitis and STD history by severity of disease,
California Men’s Health Study, 2002–2006*.
Total Pca
{ non Aggressive Pca
{ Aggressive PCa
1
No. of Cases RR (95% CI) No. of Cases RR (95% CI) No. of Cases RR (95% CI)
Prostatitis No 1484 1.00 924 1.00 524 1.00
Yes 147 1.30 (1.10–1.54)
a 108 1.52 (1.25–1.86)
b 39 1.00 (0.72–1.39)
Duration of prostatitis n (%) None 1484 1.00 924 1.00 524 1.00
,1 year 103 1.22 (1.00–1.49)
c 79 1.49 (1.18–1.88)
e 24 0.82 (0.54–1.24)
$1 year 36 1.50 (1.08–2.08)
d 29 1.47 (0.96–2.24) 14 1.67 (0.98–2.84)
STDs No 1142 1.00 730 1.00 391 1.00
Yes 464 1.02 (0.91–1.15) 288 1.00 (0.86–1.15) 163 1.06 (0.87–1.29)
Number of STDs n (%) 0 1142 1.00 730 1.00 391 1.00
1 195 1.06 (0.90–1.23) 122 1.03 (0.85–1.26) 67 1.08 (0.83–1.34)
$2 232 1.00 (0.87–1.15) 145 1.00 (0.83–1.21) 83 1.08 (0.84–1.39)
STDs & bladder infection No 920 1.00 572 1.00 332 1.00
Yes 686 1.04 (0.94–1.15) 445 1.09 (0.96–1.24) 222 0.94 (0.79–1.12)
Gonorrhea No 1274 1.00 812 1.00 437 1.00
Yes 345 1.07 (0.94–1.21) 216 1.06 (0.90–1.25) 118 1.05 (0.84–1.31)
Syphilis No 1516 1.00 961 1.00 524 1.00
Yes 43 1.23 (0.90–1.67) 28 1.28 (0.87–1.88) 15 1.25 (0.74–2.10)
Chlamydia No 1485 1.00 947 1.00 507 1.00
Yes 54 1.05 (0.80–1.39) 31 0.93 (0.64–1.34) 23 1.37 (0.90–2.10)
Genital warts No 1479 1.00 936 1.00 511 1.00
Yes 63 0.77 (0.60–0.99)
f 40 0.77 (0.56–1.06) 23 0.83 (0.54–1.26)
Genital herpes No 1465 1.00 928 1.00 507 1.00
Yes 78 0.86 (0.69–1.08) 46 0.88 (0.59–1.08) 30 0.99 (0.68–1.43)
Bladder infection No 1233 1.00 759 1.00 449 1.00
Yes 320 1.02 (0.90–1.15) 220 1.13 (0.97–1.32) 92 0.82 (0.65–1.02)
*Adjusted for age, race, family history, BMI, and income.
{Numbers do not add add to 1,658 cases due to missing responses.
{Numbers do not add add to 1,051 cases due to missing responses.
{Numbers do not add add to 871 cases due to missing responses.
aP=0.003.
bP=,.0001.
cP=.051.
dP=0.017.
eP=0.007.
fP=0.044.
doi:10.1371/journal.pone.0008736.t003
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African Americans Asian Americans Latinos Whites Others P het{
No. of
Cases RR (95% CI)
No. of
Cases RR (95% CI)
No. of
Cases RR (95% CI)
No. of
Cases RR (95% CI)
No. of
Cases RR (95% CI)
Prostatitis No 253 1.00 82 1.00 191 1.00 902 1.00 56 1.00 0.270
Yes 14 0.79 (0.46–
1.36)
7 1.95 (0.89–
4.24)
20 1.62 (1.02–
2.57)
a
101 1.31 (1.07–
1.62)
b
5 1.85 (0.66–
5.20)
Duration of prostatitis none 253 1.00 82 1.00 191 1.00 902 1.00 56 1.00 0.230
,1
year
9 0.77 (0.39–
1.50)
5 2.11 (0.85–
5.26)
10 1.27 (0.67–
2.41)
74 1.23 (0.97–
1.56)
5 2.49 (0.88–
7.05)
$1
year
2 0.42 (0.11–
1.71)
2 2.01 (0.49–
8.24)
8 2.05 (1.01–
4.17)
c
24 1.75 (1.16–
2.62)
d
1–
STDs No 100 1.00 76 1.00 135 1.00 780 1.00 51 1.00 0.2711
Yes 164 1.04 (0.81–
1.36)
13 1.26 (0.70–
2.28)
72 1.43 (1.07–
1.91)
e
205 0.92 (0.79–
1.07)
10 1.04 (0.52–
2.06)
Number of STDs 0 100 1.00 76 1.00 135 1.00 780 1.00 51 1.00 0.505
1 50 1.04 (0.74–
1.46)
6 1.24 (0.54–
2.85)
35 1.60 (1.10–
2.33)
f
99 0.94 (0.76–
1.16)
5 1.23 (0.49–
3.09)
$2 101 1.05 (0.80–
1.39)
7 1.60 (0.73–
3.50)
29 1.43 (0.96–
2.15)
93 0.91 (0.74–
1.13)
2 0.52 (0.13–
2.17)
STDs and bladder
infection
No 80 1.00 73 1.00 109 1.00 620 1.00 38 1.00 0.092
Yes 182 1.05 (0.81–
1.37)
17 0.89 (0.52–
1.51)
100 1.39 (1.06–
1.82)
g
365 0.97 (0.85–
1.10)
22 1.58 (0.93–
2.70)
Gonorrhea No 111 1.00 81 1.00 156 1.00 875 1.00 51 1.00 0.342
Yes 153 1.12 (0.88–
1.44)
8 1.16 (0.56–
2.41)
51 1.39 (1.01–
1.91)
h
124 0.94 (0.78–
1.14)
9 1.43 (0.70–
2.92)
Syphilis No 223 1.00 84 1.00 182 1.00 969 1.00 58 1.00 0.419
Yes 17 1.32 (0.80–
2.17)
4 3.72 (1.35–
10.26)
i
8 1.38 (0.64–
2.93)
13 0.93 (0.54–
1.61)
1 0.91 (0.12–
6.66)
Chlamydia No 216 1.00 83 1.00 181 1.00 949 1.00 56 1.00 0.148
Yes 18 1.00 (0.62–
1.63)
3 5.55 (1.70–
18.09)
j
6 1.82 (0.80–
4.15)
26 0.88 (0.59–
1.32)
1 1.39 (0.19–
10.18)
Gential warts No 225 1.00 87 1.00 183 1.00 927 1.00 57 1.00 0.696
Yes 9 0.55 (0.28–
1.07)
0 – 4 0.44 (0.16–
1.19)
49 0.93 (0.70–
1.25)
1 0.58 (0.08–
4.25)
Genital herpes No 218 1.00 85 1.00 175 1.00 931 1.00 56 1.00 0.946
Yes 19 0.91 (0.57–
1.46)
3 1.20 (0.38–
3.81)
11 1.16 (0.63–
2.13)
44 0.78 (0.58–
1.06)
1 0.75 (0.10–
5.54)
Bladder infection
No 191 1.00 82 1.00 151 1.00 766 1.00 43 1.00 0.413
Yes 47 0.90 (0.65–
1.24)
7 0.73 (0.34–
1.58)
38 1.06 (0.74–
1.52)
214 1.03 (0.88–
1.20)
14 1.96 (1.06–
3.61)
k
*adjusted for age, family history, BMI, and income.
{P heterogenity by racial/ethnic group.
aP=0.043.
bP=0.010.
cP=0.048.
dP=0.007.
eP=0.016.
fP=0.015.
gP=0.025.
hP=0.043.
iP=0.009.
jP=0.005.
kP=0.031.
doi:10.1371/journal.pone.0008736.t004
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prostate cancer through PSA testing and digital rectal exams. A
key concern is whether detection bias could have influenced the
association we observed between history of prostatitis and prostate
cancer risk. To address this issue, we conducted stratified analysis
by laboratory records of number of PSA tests during follow-up as
well as by history of BPH, which is also associated with incidental
detection of prostate cancer. Our finding of no evidence of
heterogeneity in effects between prostatitis and prostate cancer
across strata of no PSA test (note, 80% of the 826 cases within this
strata had a record of PSA testing within a five year period prior to
baseline), 1–2 PSA test(s), and 3 or more PSA tests would suggest
that our overall positive association may not be significantly
influenced by detection issues. However, there are limitations in
this analysis given the small numbers per stratum that may result
in chance findings and/or limited ability to detect effects such as
seen for the stratum of 1–2 PSA tests (n=27 prostate cases
reporting history of prostatitis). In particular, the stratum of 1–2
PSA tests would likely represent men undergoing routine screening
with an equal opportunity for prostate cancer detection—with the
lack of a clear association among this subgroup, results concerning
our effort to evaluate detection bias should be interpreted with
caution. These issues also apply to our evaluation of duration of
prostatitis symptoms in which the positive association we observed
may be biased due to increased opportunity of prostate cancer
detection with greater length of contact with physicians. Again, in
our stratified analysis by number of PSA tests, there is the
suggestion that there may be no differences across the levels of
PSA testing; yet, we cannot completely rule out such bias. In
addition, the lack of an association between prostatitis and prostate
Table 5. Latino relative risks and 95% CIs of prostate cancer associated with prostatitis and STD history by place of birth, California
Men’s Health Study, 2002–2006.
Latinos Asians
Born in U.S. (n=6,042) Foreign-born
{ (n=4,611) Born in U.S. (n=2,264) Foreign-born
{ (n=3,245)
No. of Cases RR (95% CI) No. of Cases RR (95% CI) No. of Cases RR (95% CI) No. of Cases RR (95% CI)
Prostatitis No 118 1.00 65 1.00 44 1.00 33 1.00
Yes 10 1.39 (0.73–2.67) 8 1.62 (0.77–3.41) 0 – 5 2.66 (1.02–6.95)
a
STDs No 93 1.00 34 1.00 40 1.00 33 1.00
Yes 33 1.15 (0.76–1.72) 35 1.87 (1.16–3.02)
b 4 0.66 (0.24–1.86) 5 1.24 (0.48–3.21)
Number of STDs 0 93 1.00 34 1.00 40 1.00 33 1.00
1 17 1.16 (0.68–1.98) 17 2.46 (1.36–4.44)
c 2 0.58 (0.14–2.42) 3 1.94 (0.59–6.38)
$2 13 1.25 (0.70–2.25) 14 1.75 (0.93–3.28) 2 0.83 (0.20–3.51) 2 1.06 (0.25–4.50)
Gonorrhea No 107 1.00 40 1.00 42 1.00 36 1.00
Yes 19 1.02 (0.63–1.67) 29 1.95 (1.20–3.16)
d 2 0.47 (0.11–1.97) 2 0.71 (0.17–2.98)
*adjusted for age, family history, BMI, and income.
{Born in Mexico, Central/South America.
aP=0.045.
bP=0.014.
cP=0.003.
dP=0.007.
{Born in Asia.
doi:10.1371/journal.pone.0008736.t005
Table 6. Multivariate relative risks and 95% CIs of prostate cancer associated with prostatitis and STD history by number of PSA
tests during follow-up, California Men’s Health Study, 2002–2006*.
No. of PSA tests during follow-up
None 1 or 2 3 or more P het
No. of Cases RR (95% CI) No. of Cases RR (95% CI) No. of Cases RR (95% CI)
Prostatitis No 751 1.00 400 1.00 333 1.00 0.215
Yes 75 1.34 (1.05–1.70)
a 27 1.10 (0.75–1.63) 45 1.42 (1.03–1.94)
b
Duration of prostatitis n (%) None 751 1.00 400 1.00 333 1.00
,1 year 48 1.15 (0.85–1.54) 24 1.36 (0.90–2.06) 31 1.28 (0.88–1.85) 0.071
$1 year 20 1.71 (1.09–2.66)
c 3 0.52 (0.17–1.61) 13 2.08 (1.19–3.63)
d
*Adjusted for age, race, family history, BMI, and income.
aP=0.018.
bP=0.029.
cP=0.019.
dP=0.010.
doi:10.1371/journal.pone.0008736.t006
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possibility that detection bias may be operating in our study.
BPH typically leads to higher levels of PSA, which in turn may
increase a man’s likelihood of having a prostate biopsy and
subsequent detection of prostate cancer. The attenuation of
association between prostatitis and prostate cancer within strata of
BPH could suggest that our overall positive association between
prostatitis and prostate cancer may be largely influenced by the
presence of BPH and its affiliated increased likelihood of prostate
cancer detection. Furthermore, the significant association seen
between prostatitis and non-aggressive disease, yet no association
between prostatitis and aggressive disease also highlight possible
biases due to detection issues. We would expect the effect of
prostatitis to behave similarly for both strata of disease severity. It
is possible the association between prostatitis and non-aggressive
disease, low grade and localized tumor types often identified by
prostate cancer screening, may actually reflect a higher likelihood
of identifying screen detected disease among those with a history of
prostatitis. While our findings between prostatitis and prostate
cancer may represent a false positive association, our findings do
warrant additional research to further evaluate the relationship
between prostatitis and prostate cancer with careful attention to
underlying influences of possible detection bias.
The myriad of conditions of prostatitis differ in prevalence as
well as their associations with infectious etiology. Chronic
prostatitis/chronic pelvic pain syndrome (category III) is the most
common (.90%) and includes both inflammatory (30%–45%)
and non-inflammatory (45%–60%) forms, while acute and chronic
bacterial prostatitis (categories I and II) and asymptomatic
inflammatory prostatitis (category IV) are less common (,10%)
and are associated with inflammation [17,18,19]. With a
substantial proportion of non-inflammatory chronic prostatitis
having an unclear etiology and no association with inflammatory
pathways, the contribution of prostatitis to prostate cancer
development may not necessarily act through a chronic inflam-
mation model. To better clarify the underlying etiologic processes,
future work should evaluate the specific four categories of
prostatitis in relationship to prostate cancer risk.
The prevalence of prostatitis in our study (6.2%) is similar to
that estimated by a recent meta-analysis of five population-based
studies (8.2%) [20] and a previous study of Kaiser Permanente
Northwest (4.5%) [21]. However, our prevalence among Whites
(7.2%) is much lower than that observed among men in the HPFS
(15.9%) [3], the majority of whom are White health professionals.
This difference between cohorts is likely due to the health
professionals in the HPFS having greater knowledge and
awareness of prostatitis conditions and a lesser degree of
misclassification of prostatitis history than our more general
population of California men. The Health Professionals Follow-up
Study (HPFS) [3] observed no overall association between
prostatitis and prostate cancer yet a significant increased risk of
disease among younger men reporting being routinely screened
(,55 years; RR=1.49; 95%: 1.08–2.06; P interaction=0.006). In
contrast, our study observed a significant positive overall
association between prostatitis and prostate cancer and no
evidence of interaction by age among screened men having 1 or
2 PSA tests (P interaction=0.607). Possible explanations for these
differences across studies may be due to differences in the
prevalence and assessment of PSA screening. First, the HPFS has a
high prevalence of PSA self-reported screening (,90%) in contrast
to the CMHS laboratory testing of PSA (,43%). The lower
prevalence of PSA testing in the CMHS limits our ability to detect
effects among those screened as well as raises issues related to the
influence of detection bias as discussed previously. Second, the
HPFS distinguished between routine screening of prostate cancer
versus testing due to symptomatic conditions based on self-report
data. In contrast, we are unable to make such a distinction in our
use of laboratory records of PSA tests. Although in our
stratification of no PSA tests, 1–2 PSA test(s), and 3 or more
PSA tests, we expect the stratum of 1–2 PSA test(s) to be most
similar to the routinely screened group from the HPFS in which a
null association was observed, again we were limited here with
smaller sample size, influencing our ability to detect effects.
The racial/ethnic patterns of STD history among men in our
study mirror the nationwide trends in disease. The Centers for
Disease Control and Prevention (CDC) report higher rates of
STDs among racial/ethnic minorities in comparison to Whites,
with the exception of Asian/Pacific Islanders [22]. Similarly, in
our study a disproportionate number of African Americans
reported having STDs in comparison to other racial/ethnic
groups. In our study, we observed no overall association between
any STDs and prostate cancer, and these findings are similar to
reports from PLCO trial and HPFS that found no association
between syphilis and gonorrhea and prostate cancer [3,12].
Interestingly, the positive associations between STD history
(and gonorrhea) and prostate cancer among Latinos suggest there
may be racial/ethnic-specific effects in spite of the lack of statistical
evidence of heterogeneity across groups. Moreover, foreign-born
Latinos displayed elevated risks of prostate cancer associated with
STD history. Whether these findings may have been biased due to
detection issues related to prostate cancer screening, the positive
associations seen across strata of number of PSA tests and lack of
evidence of heterogeneous effects would suggest no large scale bias
among this particular subgroup, although we recognize the lack of
significant findings in all of the strata limits any clear conclusion.
Alternatively, these findings may suggest that STDs acquired
outside of the U.S. may be associated with an increased
susceptibility of prostate cancer. Similar to Latinos, Asian
Americans another recent immigrant group to the U.S. displayed
a comparable pattern of higher risk of prostate cancer associated
with STDs among those foreign-born. These findings further
support the observations that STDs acquired outside of the U.S.
may be related to disease. It is possible that untreated or delayed-
treatment of STDs in less developed countries allow for prolonged
infection of microbial agents and chronic inflammation, ultimately
leading to prostate cancer development. This has been previously
proposed by Sutcliffe et al. [3], who suggested that repeated
episodes of gonorrhea (or co-infections) and/or those untreated or
have delayed treatment may be associated with prostate cancer
risk among populations having a higher burden of sexually
transmitted infections. STDs such as gonorrhea, caused by Neisseria
gonorrhoeae bacterium, have been shown to infect the prostate and
elicit an inflammatory response. In the scenario, where Neisseria
gonorrhoeae is able to establish a chronic inflammation within the
prostate by either insufficient immune response, repeated
infections, or delay/lack of treatment, the local production of
inflammatory cytokines (e.g. interleukin-6 and interleukin-8) and
reactive oxygen species as well as recruitment of neutrophils and
macrophages that carry inflammatory agents (e.g. myloperoxidase
and nitric oxidase) may induce cell and genome damage leading to
increased cell proliferation. This inflammatory cascade in response
to STD infection may ultimately lead to carcinogenesis within the
prostate.
Our current study has several strengths. The prospective design
minimizes differential recall between cases and controls and the
extensive information from baseline questionnaires allowed for the
evaluation of numerous confounding factors. Our large multieth-
nic study enabled us to explore whether risk associations differed
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population has a wide range in history of prostatitis and STDs
that likely reflect the general population of California men.
Although this is not a geographical population-based study, Kaiser
Permanente provides medical care to over 6.3 million people in
California, representing ,25–30% of the general population it
serves. The relative equal access to care lessens issues related to
availability of diagnostic services for prostatitis, STDs, and
prostate cancer.
However, there are several limitations to our study. We did not
have information on history of prostatitis/STDs as a time-
dependent variable and relied on baseline information as an
approximation of relevant prostatitis/STDs history. This poses an
interesting question for future studies to evaluate the time course of
prostatitis/STDs infection on prostate cancer risk, particularly
among a young cohort of men. In addition, chance cannot be
ruled out, especially with smaller numbers in our stratified analysis
given our relatively short follow-up time in spite of our large
cohort size. Furthermore, we did not have information on the
underlying etiology of prostatitis and identifying the specific
subtype (i.e. bacterial, viral, chronic pelvic pain syndrome) may
clarify the association reported here.
In conclusion, our study results are consistent with the
hypothesis that chronic inflammation and infectious agents related
to prostatitis and STDs may be involved in prostate cancer
susceptibility. Presently, there are no established modifiable risk
factors for prostate cancer. If future studies can identify infectious
agents as etiological factors in prostate cancer development,
important public health measures can be made in reducing the
burden of this common disease.
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